Chronic High‐Dose Ketamine Fails to Induce a Cystitis‐Like Phenotype in Mice Despite High Urinary Metabolite Levels
Jill Dewez, Ashlee Caldwell, Laura Schillebeeckx, Margot De Vis, Sylvia João Poseiro Coutinho Pinto, Evy Van den Broek, Véronique Hendrickx, Katrien Luyten, Marcella Baldewijns, Jan Tytgat, Thomas Voets, Wouter Everaerts
Neurourology and urodynamics October 21, 2026 DOI: 10.1002/nau.70483 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled animal experiment Peer reviewed |
|---|---|
| Sample size | 40 |
| Population | Male and female C57BL/6 J mice |
| Intervention | Ketamine |
| Dose | 100 mg/kg |
| Duration | 12 weeks |
| Measures | spontaneous voiding assays, von Frey filaments, nesting and open field assays, histopathological analysis, LC-QTOF/MS |
| Topics | Esketamine Ketamine |
| Key findings | Chronic high-dose ketamine (100 mg/kg intraperitoneally for 12 weeks) produced high urinary and plasma concentrations of ketamine and its metabolites but no significant differences from saline controls in voiding behavior, suprapubic mechanical sensitivity, natural behavior, or bladder and kidney histopathology. The authors conclude that this mouse strain does not develop a robust ketamine-induced cystitis phenotype, highlighting limitations of rodent models for recapitulating human ketamine-induced cystitis. |
Abstract
ABSTRACT:
Aims: Ketamine‑induced cystitis (KIC) is a severe complication of chronic ketamine misuse, yet the underlying mechanisms remain poorly understood. Established rodent models have demonstrated variable changes in voiding behavior and bladder histology, without exploring the sensory mechanisms underlying altered voiding and pain at all. This study aimed to establish a murine model of chronic ketamine‐induced cystitis to investigate changes in pain behavior and sensory signaling.
Methods: Male and female C57BL/6 J mice received intraperitoneal ketamine (100 mg/kg, n = 20) or saline ( n = 20) for 12 weeks. Urine and plasma ketamine, norketamine, and dehydronorketamine concentrations were determined using LC‐QTOF/MS. Voiding behavior was assessed fortnightly using spontaneous voiding assays, suprapubic mechanical sensitivity was evaluated using von Frey filaments, and wellbeing was assessed using nesting and open field assays. Finally, histopathological analysis was performed on bladder and kidney tissues.
Results: Despite high urinary and plasma concentrations of ketamine, norketamine, and dehydronorketamine, ketamine‐treated mice showed no significant differences in voiding behavior, suprapubic sensitivity, natural behavior, or bladder and kidney histopathology compared with controls.
Conclusion: Chronic high‐dose ketamine treatment did not induce a robust phenotype of ketamine‐induced cystitis in C57BL/6 J mice, highlighting limitations of using rodent models for recapitulating human ketamine‑induced cystitis.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: Ketamine No effect
Twelve weeks of high-dose ketamine produced high urinary and plasma drug and metabolite levels but no differences from saline in voiding behavior, suprapubic sensitivity, wellbeing, or bladder and kidney histopathology.
Synthesized
Comparable studies
Other preclinical and animal studies on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Rats | 2010 | Observational study | |
| Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Conscious rats | 1997 | Dose-response study with microdialysis and behavioral testing | |
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites Mice | 2016 | Preclinical study | |
| The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate Spinal neurons in decerebrate or pentobarbitone-anaesthetized cats and rats | 1983 | Experimental study | |
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Mice | 2015 | Experimental study |
Citations in the library
Cites 3
- The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. Addiction April 28, 2025
- Can We Better Understand, Diagnose, and Treat Ketamine-Induced Uropathy, and Can It Be Reversed? ICI-RS 2024. Neurourology and urodynamics March 1, 2025
- Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clinical radiology October 2010